Phaos Technology Holdings (Caym POAS PHARMA
Company Overview
Phaos Technology Holdings (Cayman) Limited, through its subsidiary, Phaos Technology Pte. Ltd., engages in the manufacturing and commercialization of advanced microscopy-related solutions, technologies, and products in Singapore. The company offers Optonano that enables users to view live and still images for construction of high-quality image of larger sample areas; PT-Industrial for use in material study, failure analysis, simple measuring, quality control, inspection, and manufacturing; and PT-Metrology, which provides dimensional measurements with a single key operation. It also provides PT-Biology to create specialized images needed in the biomedical sector; PT-Stereo, a stereo microscope designed to provide clear magnified stereoscopic images that amplify solid or thick samples; and PT-Zoom that offers three-dimensional magnified view of samples to enhance visualization. In addition, the company offers software. The company serves manufacturing companies; biomedical service providers; and research and development institutions. The company was founded in 2017 and is based in Singapore.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.09.
Recent Developments
- Apr 2025 Revenue of $167.71K (-91.1% YoY); net profit $-5.14M.
- Trailing 12 Months Year-on-year growth — revenue -57.5%.
- 5-Year Trend Long-term compounding — revenue CAGR -49.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -49.24% |
| 1 Year: | -57.50% |
Stock Price Performance
| 1 Year: | -95.69% |
| 6 Months: | -89.82% |
| 3 Months: | -46.28% |
| 1 Month: | -10.27% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)36.79 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -49.2% CAGR over 5 years.
- Trading 97.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | POAS Phaos Technology Holdings (Caym PHARMA | 0.17 | -0.45 | $2.80M | 0.00% | -73.54% | - | -49.24% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Apr 2023 | Apr 2024 | Apr 2025 |
|---|---|---|---|
| Revenue | 650.80K | 1.88M | 167.71K |
| Cost of Revenue | 536.17K | 1.07M | 130.64K |
| Gross Profit | 114.63K | 811.17K | 37.07K |
| Operating Expenses | 1.80M | 3.20M | 4.03M |
| Operating Income | -1.68M | -2.39M | -3.99M |
| EBITDA | -1.45M | -2.14M | -4.94M |
| Interest Expense | 25.07K | 43.54K | 8.46K |
| Pretax Income | -1.67M | -2.36M | -5.14M |
| Tax Provision | 0 | 0 | 0 |
| Net Income | -1.67M | -2.36M | -5.14M |
| Diluted EPS | -0.62 | -0.18 | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Apr 2023 | Apr 2024 | Apr 2025 | Apr 2026 |
|---|---|---|---|---|
| Total Assets | 1.38M | 5.18M | 1.93M | 6.68M |
| Current Assets | 909.30K | 4.73M | 1.52M | 6.37M |
| Cash & Equivalents | 54.10K | 2.31M | 129.55K | 762.23K |
| Inventory | 151.52K | 187.58K | 310.01K | 543.71K |
| Receivables | 548.20K | 412.59K | 38.38K | 1.75K |
| Total Liabilities | 4.40M | 2.26M | 3.90M | 1.38M |
| Current Liabilities | 3.75M | 2.05M | 3.80M | 1.25M |
| Long Term Debt | 574.56K | 133.98K | 78.37K | 20.05K |
| Total Debt | 885.35K | 792.58K | 265.82K | 451.04K |
| Total Equity | -3.02M | 2.92M | -1.96M | 5.30M |
| Shares Outstanding | - | - | 13.30M | 16.45M |
Cash Flows (Annual)
Figures in USD.
| Metric | Apr 2023 | Apr 2024 | Apr 2025 | Apr 2026 |
|---|---|---|---|---|
| Operating Cash Flow | -1.79M | -1.61M | -3.65M | -10.90M |
| Investing Cash Flow | -187.89K | -1.65M | -332.84K | 468.40K |
| Financing Cash Flow | 1.91M | 5.52M | 1.80M | 10.98M |
| Capital Expenditure | -217.64K | -121.32K | -240.21K | -39.72K |
| Free Cash Flow | -2.01M | -1.73M | -3.89M | -10.94M |
| Net Change in Cash | -66.50K | 2.26M | -2.18M | 542.85K |
Ratios (Annual)
Figures in %.
| Metric | Apr 2023 | Apr 2024 | Apr 2025 |
|---|---|---|---|
| Gross Margin % | 17.6% | 43.1% | 22.1% |
| Operating Margin % | -258.2% | -126.8% | -2,381.3% |
| Net Margin % | -256.3% | -125.3% | -3,063.1% |
| ROE % | 55.3% | -80.8% | 261.7% |
| ROCE % | 71.0% | -76.0% | 214.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | UBS Group AG | 2.19% | 360.39K | $59.10K |
| 2 | Jane Street Group, LLC | 0.74% | 121.94K | $20.00K |
| 3 | Xtx Topco Ltd | 0.64% | 105.90K | $17.37K |
| 4 | Virtu Financial LLC | 0.37% | 61.13K | $10.02K |
| 5 | Susquehanna International Group, LLP | 0.20% | 32.56K | $5.34K |
| 6 | Two Sigma Investments, LP | 0.12% | 19.37K | $3.18K |
| 7 | Citadel Advisors Llc | 0.10% | 16.40K | $2.69K |
| 8 | Tower Research Capital LLC (TRC) | 0.09% | 15.00K | $2.46K |
| 9 | Caitong International Asset Management Co., Ltd | - | 1 | $0 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for POAS
15 shares become 1 as Phaos (POAS) overhauls its stock - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxOSnhYZ3AxVVYzcXczR2JabDdXSmtSQVJaaU9BNFZZWlpXMk01cjZ2a0lxOElfVVBGOXNrcjhEX3FUOXhJSUlDWklsU3dFampvZDZBNklsQVRLN1BoanMweE92NldiOVlWSEFEZlJydDQ1QmNkMlBqUmtZM2Y5b1FtYW9sZ3VMVWxqRUZvVn…
POAS Technical Analysis & Stock Price Forecast - Intellectia AI
<a href="https://news.google.com/rss/articles/CBMiWkFVX3lxTE5nUjRTTzZVb1drZWpBU1I5UWtobk16bjAyY1hQaVJ3eDkzbnoySDZiVkhuQ3ZYcENBT3B3bEJwM3h2NVBNOWZPQUNEbkJLLUFka1Z4aHVMQTQ2dw?oc=5" target="_blank">POAS Technical Analysis & Stock Price Forecas…
Monday's session: gap up and gap down stocks - ChartMill
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxQMFFNZ0V0RWpLTG00dHhoVG5qdy1Td1dkN0MwYkVBZ1huUktNMzNwN2dYRTBIZ1VlNWJkUG16S3BvYUV3NVhpSUsxVXR3VHBXMkZDVGJ5TV94QzZIa05aZFJJOW96dzk4WUMzVWI4eHM3UmxIZS1LS0dFaDVMVkFFTlBoMkpjYk55QUFzaW…
Phaos Technology Holdings (Cayman) Limited Announces Results of Extraordinary General Meeting - marketscreener.com
<a href="https://news.google.com/rss/articles/CBMi3AFBVV95cUxNYUJlNDRTUzlCVnpfM3AybW1tMmJKbHNsd05lN0pJY3EyRng2X2wyRFRQNjkwWXJXb3ZqVnBzTjVxTDFpeGtlUU5YMGdJek9VWWw1MElybS15UmFsWmhBRFVYQ19Ra0FXZzRkanpoYnUzUzlhOGlqeVVlR0dUVFp2d0R4N21sUUdvZmhXNH…
POAS Stock Price and Chart — AMEX:POAS - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiWkFVX3lxTE14c2hsb1VNRHBlZXg3R2Z0NlUwYV8xVkFOYjNvZ3FySkZqMTJidEZmeGpQWDZSM1BialAxYmhsLTR0MmRrMGluTWVjSTZQYzljU2U2djJXVEpJZw?oc=5" target="_blank">POAS Stock Price and Chart — AMEX:POAS</a>&nb…
Market Movers | Winners: FGNX, RIME, ATOM | Losers: POAS, PFSA, INTS - Trefis
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxNVkREUUNNbThqVlpySk1jeFZhWEptTERRWGJjbk9sbGpubS1jdGlLWGRQRmpiVlFROVFNY1NWMDk4Nk5lZkVzZ2FfY3JxM2pINGdrQ08wTmQwVG4wVXpZcDRsLXBrVUR3OGlQOGVMbjZPalNGVUxkMFMzdVludjVLZHBhTFRYaGdLVDVLdn…
POAS — Frequently Asked Questions
What is the current share price of Phaos Technology Holdings (Caym (POAS)?
As of 2026-09-19 21:16 PDT, Phaos Technology Holdings (Caym (POAS) trades at $0.17 on NYSE American. Its 52-week range is $0.16 to $6.60.
What is the market capitalisation of POAS?
Phaos Technology Holdings (Caym (POAS) has a market capitalisation of $2.80M on NYSE American.
What is the P/E ratio of POAS?
POAS trades at a trailing price-to-earnings (P/E) ratio of -0.45. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.24.
Is POAS a good stock to buy?
This page provides a data-driven analysis of Phaos Technology Holdings (Caym (POAS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.